T. Rowe Price Biotech ETF
TDNA - ETF AI Analysis
Top Page
T. Rowe Price Biotech ETF (TDNA)
TDNA, the T. Rowe Price Biotech ETF, has a solid but not top-tier rating, largely supported by strong, profitable leaders like United Therapeutics, Vertex Pharmaceuticals, Argenx, and Natera, which bring robust revenue growth, positive earnings sentiment, and bullish technical trends to the portfolio. However, several smaller holdings such as Kodiak Sciences, Insmed, Vaxcyte, and Revolution Medicines face significant financial challenges, losses, and bearish technical signals, which weigh on the fund’s overall quality. The main risk factor is the ETF’s focus on early- and mid-stage biotech companies, where high R&D costs, regulatory uncertainty, and volatile stock performance can lead to larger swings in value.
TDNA vs. SPDR S&P 500 ETF (SPY)
- AUM
- 11.54M
- Region
- Global
- Expense Ratio
- 0.55%
- Beta
- 0.36
- Issuer
- T. Rowe Price
- Inception Date
- Sep 16, 2026
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
TDNA Summary
TDNA is the T. Rowe Price Biotech ETF, an actively managed fund that focuses on biotechnology companies, mainly in the U.S. health care sector. It invests in businesses working on new medicines and therapies, including well-known names like Vertex Pharmaceuticals and United Therapeutics. Someone might consider this ETF if they want growth potential from cutting-edge drug and treatment development, without having to pick individual biotech stocks. However, biotech shares can be very volatile and sensitive to drug trial results and regulation, so the ETF’s value can go up and down sharply.
How much will it cost me?
This ETF has an annual expense ratio of 0.55%, which means you’ll pay about $5.50 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed and focuses on a specialized biotech sector, which typically costs more to run than broad, passively managed index funds.
What would affect this ETF?
This biotech ETF could benefit if medical breakthroughs, strong drug approvals, and supportive health-care policies boost the prospects of its global holdings like Argenx, Vertex, and Alnylam. On the downside, higher interest rates, tighter regulations on drug pricing or clinical trials, and setbacks in company pipelines could hurt investor sentiment and make this concentrated health-care, biotechnology exposure more volatile.
TDNA Top 10 Holdings
TDNA is a pure biotech play, with nearly all its firepower aimed at health care innovators around the globe. United Therapeutics and Vertex act as steady anchors, rising on solid revenue and profitable growth. Moderna has been climbing again, powered by renewed optimism around its pipeline, while Kodiak Sciences has surged, giving the fund a shot of high‑risk, high‑reward energy. On the flip side, Insmed and Revolution Medicines have been lagging, reminding investors that early‑stage biotech can be a bumpy ride even in a focused, research‑driven portfolio.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 ARGX | Argenx Se | 5.40% | $618.88K | $60.31B | 9.88% | 79Outperform |
 KYMR | Kymera Therapeutics | 4.87% | $557.90K | $11.67B | 112.78% | 56Neutral |
 KOD | Kodiak Sciences | 3.07% | $352.17K | $6.79B | 457.00% | 35Underperform |
 INSM | Insmed | 2.68% | $306.73K | $26.21B | -37.66% | 43Neutral |
 MRNA | Moderna | 2.44% | $279.93K | $101.49B | 841.65% | 59Neutral |
 PCVX | Vaxcyte | 2.33% | $266.57K | $10.50B | 50.28% | 50Neutral |
 RYTM | Rhythm Pharmaceuticals | 2.23% | $255.93K | $7.90B | 12.32% | 59Neutral |
 UTHR | United Therapeutics | 2.12% | $243.10K | $25.07B | 29.71% | 79Outperform |
 RVMD | Revolution Medicines | 2.20% | $252.33K | $41.76B | 181.99% | 52Neutral |
 NTRA | Natera | 1.72% | $197.48K | $45.24B | 54.71% | 73Outperform |
TDNA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TDNA, the sentiment is Positive. The current price of 25.60 is above the 20-day moving average (MA) of 24.35, compared to the 50-day MA of , and compared to the 200-day MA of , indicating a neutral trend. The MACD of 0.18 indicates Negative momentum. The RSI at 56.51 is Neutral, neither overbought nor oversold. The STOCH value of 82.61 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TDNA.
TDNA Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| TDNA | $25.60 | $24.50(-4.29% Downside) | $11.54M | 0.55% | 56Neutral |
 HRTS | $39.41 | $45.65(15.81% Upside) | $58.38M | 0.75% | 67Neutral |
 OZEM | $31.73 | $47.08(48.36% Upside) | $57.97M | 0.59% | 57Neutral |
 FMED | $32.76 | $48.94(49.37% Upside) | $30.57M | 0.50% | 59Neutral |
 MEDI | $36.25 | $46.27(27.62% Upside) | $44.21M | 0.80% | 62Neutral |
 PSIL | $20.07 | $53.80(168.06% Upside) | $43.26M | 1.00% | 44Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TDNA | T. Rowe Price Biotech ETF | 25.60 | 0.11 | 0.43% | |
| HRTS | Tema Cardiovascular and Metabolic ETF | 39.41 | 5.54 | 16.36% | |
| OZEM | Roundhill GLP-1 & Weight Loss ETF | 31.73 | 0.53 | 1.71% | |
| FMED | Fidelity Disruptive Medicine ETF | 32.76 | 5.81 | 21.55% | |
| MEDI | Harbor Health Care ETF | 36.25 | 5.29 | 17.10% | |
| PSIL | AdvisorShares Psychedelics ETF | 20.07 | 3.90 | 24.11% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.